MedPath

Moderna

Moderna logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2010-01-01
Employees
5.6K
Market Cap
$30.3B
Website
http://www.modernatx.com
Introduction

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension

Phase 1/2
Recruiting
Conditions
Glycogen storage disease type 1a (GSD1a)
Interventions
First Posted Date
2024-05-27
Last Posted Date
2025-02-03
Lead Sponsor
Moderna Therapeutics Inc.
Target Recruit Count
24
Registration Number
2022-502963-39-00
Locations
🇪🇸

Hospital Universitario 12 De Octubre, Madrid, Spain

🇪🇸

Hospital Universitario Regional De Malaga, Malaga, Spain

🇫🇷

Hopital Antoine Beclere, Clamart, France

and more 3 locations

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Phase 3
Active, not recruiting
Conditions
Cytomegalovirus Infection
Interventions
Biological: Placebo
First Posted Date
2021-10-20
Last Posted Date
2024-12-24
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
7454
Registration Number
NCT05085366
Locations
🇺🇸

Central Research Associates Inc, Birmingham, Alabama, United States

🇺🇸

Accel Research Site - Achieve - Birmingham - ERN - PPDS, Birmingham, Alabama, United States

🇺🇸

SEC Clinical Research LLC - Dothan - ClinEdge - PPDS, Dothan, Alabama, United States

and more 275 locations

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Phase 2
Conditions
Cytomegalovirus Infection
Interventions
First Posted Date
2021-07-26
Last Posted Date
2025-05-21
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
291
Registration Number
NCT04975893
Locations
🇺🇸

Optimal Research, LLC, Peoria, Illinois, United States

🇺🇸

Johnson County Clin-Trials, Inc., Lenexa, Kansas, United States

🇺🇸

Alliance for Multispeciality Research, LLC, Lexington, Kentucky, United States

and more 3 locations

Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

Completed
Conditions
SARS-CoV-2
First Posted Date
2021-07-12
Last Posted Date
2023-07-17
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
50000000
Registration Number
NCT04958954
Locations
🇺🇸

Aetion Inc., New York, New York, United States

Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study

Terminated
Conditions
SARS-CoV-2
First Posted Date
2021-07-12
Last Posted Date
2023-11-28
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
20
Registration Number
NCT04958304
Locations
🇺🇸

IQVIA Call Center for United States and Canada, Durham, North Carolina, United States

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Phase 1
Completed
Conditions
Seasonal Influenza
Interventions
Biological: mRNA-1010
Biological: Placebo
Biological: Active Comparator
First Posted Date
2021-07-09
Last Posted Date
2023-10-27
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
885
Registration Number
NCT04956575
Locations
🇺🇸

Cognitive Clinical Trials - Phoenix, Phoenix, Arizona, United States

🇺🇸

Alliance for Multispecialty Research, LLC - Phoenix, Tempe, Arizona, United States

🇺🇸

Benchmark Research - Colton, CA, Colton, California, United States

and more 15 locations

Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

Completed
Conditions
Coronavirus Disease (COVID-19)
Interventions
Biological: COVID-19 Vaccine
First Posted Date
2021-06-28
Last Posted Date
2023-05-19
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
8538
Registration Number
NCT04941144
Locations
🇯🇵

Moderna selected site, Tokyo, Japan

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

First Posted Date
2021-06-15
Last Posted Date
2025-02-28
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
5161
Registration Number
NCT04927065
Locations
🇺🇸

Benchmark Research (California), Sacramento, California, United States

🇺🇸

Research Centers of America, Hollywood, Florida, United States

🇺🇸

Jacksonville Center For Clinical Research, Jacksonville, Florida, United States

and more 20 locations

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

Phase 2
Completed
Conditions
Zika Virus
Interventions
Biological: Placebo
First Posted Date
2021-06-08
Last Posted Date
2024-10-01
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
808
Registration Number
NCT04917861
Locations
🇺🇸

Meridian Clinical Research (Sioux City, IA), Sioux City, Iowa, United States

🇺🇸

Johnson County Clin-Trials, Lenexa, Kansas, United States

🇺🇸

Benchmark Research - Fort Worth, Fort Worth, Texas, United States

and more 6 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2021-06-07
Last Posted Date
2022-08-10
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
18
Registration Number
NCT04916431
Locations
🇦🇺

Nucleus Network Limited, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath